Faculty

Lindsey E. Roeker, M.D.

Clinical Studies

A Phase 3, Open-Label, Randomized Study To Evaluate The Safety And Efficacy Of BGB-16673 Compared To Pirtobrutinib In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma Scottsdale/Phoenix, AZ Jacksonville, FL Rochester, MN
The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi).